Showing results (1-10 of 174) with videos related to
Sort By:
Pageof 18
Science (New York, N.Y.)|February 1, 2024
Degradation trumps mutations in cancerR Eric Davis, Jason R WestinFuture Oncology (London, England)|March 29, 2014
Busting robustness: using cancer's greatest strength to our advantageJason R WestinClinical Lymphoma, Myeloma & Leukemia|March 22, 2014
Status of PI3K/Akt/mTOR pathway inhibitors in lymphomaJason R WestinMolecular Cancer Therapeutics|December 4, 2012
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapyJason R Westin, Razelle KurzrockBlood|July 6, 2026
The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial DesignDai Chihara, Jason R WestinClinical Lymphoma, Myeloma & Leukemia|July 2, 2016
What to Do With Success? The Optimist's Creed in Relapsed Hodgkin LymphomaAmir K Issa, Jason R WestinLeukemia & Lymphoma|November 29, 2021
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?Max J Gordon, Jason R WestinCurrent Hematologic Malignancy Reports|April 29, 2010
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratificationJason R Westin, Luis E FayadFrontiers in Oncology|December 19, 2012
Therapy of newly diagnosed follicular lymphomaJason R Westin, Sattva S NeelapuAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomesJason R Westin, Hagop Kantarjian, Razelle KurzrockPageof 18